Thermo Fisher to Buy Patheon NV
hermo Fisher Scientific has announced its intention to buy Patheon NV.
Thermo Fisher Scientific (Waltham, Massachusetts, USA) has announced its intention to buy Patheon NV (Amsterdam, The Netherlands), a manufacturer of drugs for clinical trials, for $5.2 billion as the company seeks to expand its products and services for the biopharma industry.
Thermo Fisher Chief Executive Marc Casper described the deal as a “hand in glove fit to… our fastest growing part of the business.”
The deal is expected to be completed by the end of the year, and Casper believes the purchase will allow for greater growth potential in the long run with “very interesting opportunities to build out their footprint in AsiaâPacific.” An area Thermo Fisher feels it has yet to penetrate.
“It’s really about expanding our capabilities,” said Casper. “We want to be able to offer our customers a menu of services.”
The buyout of Patheon is expected to more than double Thermo Fisher’s sales in the biopharma market.
For more information please visit, www.thermofisher.com
Understanding FDA Recommendations for N-Nitrosamine Impurity Levels
April 17th 2025We spoke with Josh Hoerner, general manager of Purisys, which specializes in a small volume custom synthesis and specialized controlled substance manufacturing, to gain his perspective on FDA’s recommendations for acceptable intake limits for N-nitrosamine impurities.
University of Rouen-Normandy Scientists Explore Eco-Friendly Sampling Approach for GC-HRMS
April 17th 2025Root exudates—substances secreted by living plant roots—are challenging to sample, as they are typically extracted using artificial devices and can vary widely in both quantity and composition across plant species.
Determining the Serum Proteomic Profile in Migraine Patients with LC–MS
April 17th 2025Researchers used liquid chromatography–mass spectrometry (LC–MS) in their proteomic analysis to compare the serum proteome of migraine patients with healthy controls and to identify differentially expressed proteins as potential migraine biomarkers.
